Incyte (INCY): Novartis Data Bodes Well For Incyte - RBC

October 25, 2016 7:51 AM EDT
Get Alerts INCY Hot Sheet
Price: $102.88 +0.90%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade INCY Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst, Simos Simeonidis, reiterated his Outperform rating on shares of Incyte (NASDAQ: INCY) after Novartis (NYSE: NVS), INCY's ex-US parter, reported $149M in 3Q16 Jakavi sales, beating consensus of $147M but lower than his $153M estimate. That said, royalties could be up 57% y/y.

Full detail will come out on INCY's 3Q16 earnings call, Tuesday November 1st, mid morning.

No change to the price target of $113.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $88.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital, Earnings

Add Your Comment